IGI files IND application with US FDA for first-in-class cancer immunotherapy targeting solid tumors
Pfizer will pay Starna $330 million upfront, with the latter eligible for up to $2.3 billion in additional milestone payments tied to development and commercial achievements
Subscribe To Our Newsletter & Stay Updated